Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum. by Bevan-Jones, W Richard et al.
Neuroinflammation and protein aggregation
co-localize across the frontotemporal
dementia spectrum
W. Richard Bevan-Jones,1,* Thomas E. Cope,2,3,* P. Simon Jones,2 Sanne S. Kaalund,2
Luca Passamonti,2,4 Kieren Allinson,5 Oliver Green,4 Young T. Hong,6 Tim D. Fryer,6
Robert Arnold,1 Jonathan P. Coles,7 Franklin I. Aigbirhio,6 Andrew J. Larner,8
Karalyn Patterson,2,3 John T. O’Brien1,# and James B. Rowe2,3,#
*,#These authors contributed equally to this work.
The clinical syndromes of frontotemporal dementia are clinically and neuropathologically heterogeneous, but processes such as neuroin-
flammation may be common across the disease spectrum. We investigated how neuroinflammation relates to the localization of tau and
TDP-43 pathology, and to the heterogeneity of clinical disease. We used PET in vivo with (i) 11C-PK-11195, a marker of activated
microglia and a proxy index of neuroinflammation; and (ii) 18F-AV-1451, a radioligand with increased binding to pathologically
affected regions in tauopathies and TDP-43-related disease, and which is used as a surrogate marker of non-amyloid-b protein aggrega-
tion. We assessed 31 patients with frontotemporal dementia (10 with behavioural variant, 11 with the semantic variant and 10 with
the non-fluent variant), 28 of whom underwent both 18F-AV-1451 and 11C-PK-11195 PET, and matched control subjects (14 for 18F-
AV-1451 and 15 for 11C-PK-11195). We used a univariate region of interest analysis, a paired correlation analysis of the regional rela-
tionship between binding distributions of the two ligands, a principal component analysis of the spatial distributions of binding, and a
multivariate analysis of the distribution of binding that explicitly controls for individual differences in ligand affinity for TDP-43 and
different tau isoforms. We found significant group-wise differences in 11C-PK-11195 binding between each patient group and controls
in frontotemporal regions, in both a regions-of-interest analysis and in the comparison of principal spatial components of binding. 18F-
AV-1451 binding was increased in semantic variant primary progressive aphasia compared to controls in the temporal regions, and
both semantic variant primary progressive aphasia and behavioural variant frontotemporal dementia differed from controls in the ex-
pression of principal spatial components of binding, across temporal and frontotemporal cortex, respectively. There was a strong posi-
tive correlation between 11C-PK-11195 and 18F-AV-1451 uptake in all disease groups, across widespread cortical regions. We con-
firmed this association with post-mortem quantification in 12 brains, demonstrating strong associations between the regional densities
of microglia and neuropathology in FTLD-TDP (A), FTLD-TDP (C), and FTLD-Pick’s. This was driven by amoeboid (activated)
microglia, with no change in the density of ramified (sessile) microglia. The multivariate distribution of 11C-PK-11195 binding related
better to clinical heterogeneity than did 18F-AV-1451: distinct spatial modes of neuroinflammation were associated with different fron-
totemporal dementia syndromes and supported accurate classification of participants. These in vivo findings indicate a close association
between neuroinflammation and protein aggregation in frontotemporal dementia. The inflammatory component may be important in
shaping the clinical and neuropathological patterns of the diverse clinical syndromes of frontotemporal dementia.
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Introduction
Frontotemporal dementia (FTD) encompasses a clinically and
pathologically heterogeneous group of neurodegenerative con-
ditions, including the behavioural variant (bvFTD) (Rascovsky
et al., 2011), non-fluent variant primary progressive aphasia
(nfvPPA) and semantic variant primary progressive aphasia
(svPPA) (Gorno-Tempini et al., 2011). In recent years, attention
has focused on understanding the pathogenic role of protein
misfolding and aggregation, which is a cardinal feature of the
post-mortem diagnostic criteria for frontotemporal lobar de-
generation (FTLD) (Mackenzie et al., 2010). However, there
are several different pathological proteins and aggregationmor-
phologies in FTD, with generally weak correlations between
clinical syndrome and the type of pathological protein (Seelaar
et al., 2011) [with the exception of svPPA, which is strongly
associated with TAR DNA-binding protein 43 (TDP-43) type
C neuropathology] (Spinelli et al., 2017). However, other
neuropathological processes may be present in common across
these diverse clinical syndromes and present potential thera-
peutic targets. In particular, there is converging evidence for the
role of neuroinflammation in neurodegenerative dementias,
including FTD, from genetic associations (Guerreiro et al.,
2013; Rayaprolu et al., 2013; Broce et al., 2018), CSF (Sjogren
et al., 2004; Woollacott et al., 2018), epidemiology (Miller
et al., 2013, 2016), post-mortem tissue (Venneti et al., 2008;
Lant et al., 2014) and animal models (Yoshiyama et al., 2007;
Bhaskar et al., 2010; Yin et al., 2010). Both the intensity of neu-
roinflammation and its distribution across the brain may be
relevant determinants of the clinical syndrome. Here we aim to
build on recent in vivo studies of Alzheimer’s disease, which
demonstrate that neuroinflammation correlates spatially with
tau aggregation (Dani et al., 2018), by assessing whether this
association extends to FTD, which is associated with many dif-
ferent conformations of pathological tau, or other protein
aggregates such as TDP-43.
PET allows the topographic quantification of specific mol-
ecules using radioligands. In this study, we measured neuro-
inflammation and protein aggregation in vivo in patients
with bvFTD, svPPA and nfvPPA, to answer key questions
regarding the relationship of these pathophysiological proc-
esses. 11C-PK-11195, which binds to the translocator protein
(TSPO) that is expressed on the outer mitochondrial mem-
brane of activated microglia, is a robust and sensitive marker
of microglial activation with an established role as a proxy
for neuroinflammation in neurodegenerative diseases
(Stefaniak and O’Brien, 2016). 18F-AV-1451 was originally
developed to bind to paired helical filament tau in
Alzheimer’s disease (Zhang et al., 2012; Chien et al., 2013;
Xia et al., 2013), and has been extensively used in
Alzheimer’s and non-Alzheimer’s diseases. Elevated in vivo
binding is seen in tauopathies characterized by straight fila-
ments (Bevan-Jones et al., 2016; Passamonti et al., 2018;
Smith et al., 2017; Jones et al., 2018), albeit with generally
lower binding affinity than in Alzheimer’s disease, and also
in TDP-43-related disease (Bevan-Jones et al., 2018a, 2018b;
Makaretz et al., 2018). It also has low affinity for amyloid-b
and a-synuclein (Xia et al., 2013). Therefore, although the
molecular interpretation of increased binding is incompletely
understood (Marquie´ et al., 2015; Sander et al., 2016), this
elevated in vivo binding suggests that 18F-AV-1451 repre-
sents a proxy index of aggregated non-amyloid-b patho-
logical proteins across the FTD spectrum.
Given the evidence for differences in affinity of 18F-AV-
1451 for different tau and TDP-43 conformational targets,
our analysis strategy concentrates on the relative topographic-
al distribution of binding across regions within each individ-
ual, rather than the simple magnitude of binding. In this way,
we explicitly control for difference in binding affinity between
syndromes and protein strains within each syndrome.
We test the hypotheses that, in FTD, neuroinflammation
and protein aggregation are both increased in frontotempo-
ral regions compared to controls, and that neuroinflamma-
tion and protein aggregation regionally co-localize in each
FTD syndrome, consistent with the syndrome-specific neuro-
pathological distributions (e.g. co-localization of neuroin-
flammation and protein aggregation in the temporal pole of
patients with svPPA). We use data-driven approaches to
PET imaging to elucidate the spatial modes of neuroinflam-
mation associated with FTD, and machine learning based on
multi-dimensional scaling of distributional dissimilarities, to
investigate whether the cortical distribution of neuroinflam-
mation and protein aggregation can accurately discriminate
diagnostic groups thereby illustrating their mechanistic
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importance. The association between protein aggregation
(tau or TDP-43) and inflammation (microglia) in the imag-
ing data is supported by immunohistochemistry of post-mor-
tem tissue from patients with FTD associated with
FTLD-TDP types A and C, and FTLD-Pick’s disease.
Materials and methods
As part of the NIMROD study (Bevan-Jones et al., 2017), 31
patients (10 with bvFTD, 11 with svPPA and 10 with nfvPPA)
underwent PET scanning with 18F-AV1451. Twenty-eight of the
31 (nine with bvFTD, nine with svPPA and 10 with nfvPPA)
also underwent a PET scan with 11C-PK-11195. The order of
scans was randomized. Fourteen healthy control participants
underwent 18F-AV-1451 PET and, to minimize radiation expos-
ure in healthy individuals, a different group of 15 healthy partic-
ipants underwent 11C-PK-11195 PET scanning. Genetic and
amyloid status (by PET or CSF biomarkers) for patients were
tested if clinically indicated.
PET with 18F-AV-1451 and 11C-PK-11195 was performed on
a GE Discovery 690 PET/CT (GE Healthcare) with a low dose
CT for attenuation correction or on a GE Advance PET scanner
(GE Healthcare) with a 15-min 68Ge/68Ga transmission scan
for attenuation correction. The PET scan itself used dynamic
imaging for 90 (18F-AV-1451) and 75 (11C-PK-11195) min, re-
spectively. All radioligands were prepared at the Wolfson Brain
Imaging Centre (WBIC), University of Cambridge, with high
radiochemical purity (495%). Each subject underwent contem-
poraneous 3T MRI using a Siemens Magnetom Skyra, Verio or
Tim Trio (www.medical.siemens.com). A high-resolution T1-
weighted sequence was acquired (176 slices of 1.0 mm thick-
ness, echo time = 2.98 ms, repetition time = 2300 ms, flip angle
= 9, acquisition matrix 256  240; voxel size = 1  1  1
mm3) and used for tissue segmentation (grey and white matter
along with CSF), and for non-rigid registration of standard
space regions of interest. For both ligands, non-displaceable
binding potential (BPND) was calculated in 83 regions of inter-
est, defined by a Hammers atlas modified to include the mid-
brain and the dentate nucleus of the cerebellum, by kinetic
modelling using a simplified reference tissue model, with cerebel-
lar grey matter as reference region for 18F-AV-1451 (Passamonti
et al., 2018) and supervised cluster analysis used to define the
11C-PK-11195 reference region (Yaqub et al., 2012). Prior to
kinetic modelling, all region of interest data were corrected for
CSF contamination of the region (i.e. partial volume corrected)
through division by the mean region grey plus white matter
fraction, determined using tissue probability maps smoothed to
PET spatial resolution.
Four data analysis approaches were used, each designed to
answer a different focused question and to explicitly control for
expected between-subject and between-region differences in lig-
and affinity.
As a first-stage data exploration of between-group differences,
a repeated-measures ANOVA was performed across the 83
regions, including age as a covariate and Greenhouse-Geisser
penalization of degrees of freedom to correct for non-sphericity.
Post hoc t-tests were then performed between each group, cor-
rected for false discovery rate (FDR) over regions.
Second, to examine the relationship between neuroinflamma-
tion and protein aggregation in each disease group, a correlation
between the regional BPND of each ligand was performed. PET
scanning with any ligand characteristically results in a general
pattern of lower BPND in brain regions such as temporal lobe
and higher BPND in deep brain nuclei. We were concerned that
such non-specific effects might drive apparent correlations, and
weak correlations were observed between our cohorts of con-
trols for each ligand (Supplementary Fig. 1). To control for this,
we examined the between-ligand correlation within each disease
group both with and without subtraction of the control mean
BPND for each of the 83 regions of interest. We then assessed
whether the association between the regional BPND of the two
ligands was independent of atrophy. To do this, we first calcu-
lated a combined grey and white matter volume t-score for each
brain region and disease group, representing the degree of atro-
phy in that region compared to controls (we observed that this
combined grey and white matter t-score was more strongly
related to ligand binding than either tissue class alone, and
therefore report this as the most conservative correction and in-
formative association). We then calculated partial correlations
between the two ligands, with the effect of atrophy partialled
out, as well as between each ligand and atrophy individually,
with the effect of the other ligand partialled out.
Third, to elucidate the topographical patterns of inflammation
and protein aggregation in FTD, we entered the BPND of each
ligand in each of the 83 regions of interest into a principal com-
ponent analysis. Components were retained by Cattell’s criterion
(i.e. to the elbow of the scree plot) and then tested for group dif-
ferences across diagnosis in a repeated measures ANOVA. Post
hoc t-tests examined group differences in the expression of each
topographical pattern. These first three analyses were performed
in SPSS Statistics version 25 (IBM).
Finally, we undertook an analysis of the relative distribution
of ligand binding potential for each ligand for every individual.
This used previously published non-parametric methods (Bevan-
Jones et al., 2016), that were explicitly designed to control for
between-subject differences in the scaling of each ligand, such as
might result from differences in the affinity of 18F-AV-1451 for
different conformations of tau or TDP-43, as well as spatial de-
pendence between adjacent regions in PET data due to signal
spread. These methods can be conceptualized as analogous to
multi-voxel pattern analysis techniques for functional MRI
(Kriegeskorte et al., 2008), but rather than attempting to classify
observed stimuli within an individual on the basis of their repre-
sentational similarity, here we are attempting to classify individ-
uals on the basis of the similarity of relative ligand BPND
distributions within their brains, blinded to overall differences in
binding affinity. To do this, for each ligand and every individual
separately, the parcellated data were converted to 83-element
linear vectors. For each ligand separately, the resultant vectors
were non-parametrically correlated (Spearman’s rho) pairwise
between individuals, resulting in two matrices that represented
the similarity of each individual’s scan to each other individual
for that ligand. The inverse of these matrices (i.e. the between-
individual dissimilarities) were used to calculate a 2D scaling for
each disease subgroup pair, using the squared metric stress dis-
tance criterion of the ‘mdscale’ function in MATLAB R2017b
(Mathworks). The resulting locations in 2D space formed the
inputs to a 10-fold cross-validated linear support vector machine
(CV-SVM) for between-group classification based on each lig-
and separately. Statistical significance of the classification was
assessed by comparison of the loss function of the CV-SVM
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against a null distribution of loss functions created by 1000 rep-
etitions of the same procedure for identical data but shuffled
group assignment labels. For those individuals who underwent
scanning with both ligands, the CV-SVM process was repeated
on multi-modal, 4D scaling. To confirm that our machine learn-
ing results were not significantly influenced by age or sex, we
attempted supplementary classifications based on these factors.
Additionally, we performed quantitative immunohistochemis-
try on 12 post-mortem cases from the Cambridge Brain Bank to
augment the imaging results. From our database of specimens,
we selected three cases of FTLD-Pick’s (a tauopathy), three cases
of FTLD-TDP type C and three cases of FTLD-TDP type A,
and compared these to three cases of Braak stage V Alzheimer’s
disease. For each case, fixed brain tissue was sampled from the
prefrontal cortex [Brodmann area (BA) 44], middle temporal
cortex (BA22/21), parietal cortex (BA7), and occipital cortex
(BA17/18). These were embedded in paraffin, and sectioned at
10 mm. For each region, two neighbouring sections were stained
by immunohistochemistry using antibodies directed against
CD68 (clone PG-M1, Dako), a marker of microglia and macro-
phages, and against the relevant pathological protein: hyper-
phosphorylated tau (AT8, MN1020, Thermo Scientific) or
TDP43 (TIP-PTD-P02, Cosmo Bio Co Ltd.).
The number of protein aggregates, microglia, and cell nuclei
were counted in series of fields of view placed uniformly ran-
domly onto each section: a virtual grid with uniform distances
between lines in the x and y direction, 1875 mm  1875 mm,
was superimposed onto each section. The position of fields of
view was at the intersections of the grid lines, but only where
lines crossed overlapping grey matter. The fields of view were
125 mm  125 mm and counting was done under a 40 object-
ive lens.
A microglial cell was counted when CD68 reactivity was vis-
ible over or around a cell nucleus. Based on the morphology,
cells positive for the CD68 staining were divided into ramified
microglia, amoeboid microglia and macrophages. In FTLD-
Pick’s, Pick bodies and glial tau inclusions were counted. In
FTLD-TDP inclusions type A and C, dystrophic neurites, and
lentiform intranuclear inclusions and neuronal cytoplasmic
inclusions, respectively were counted. In Alzheimer’s disease,
neurofibrillary tangles and neuritic plaques were counted. The
densities of pathology, microglia and cell nuclei were calculated
by dividing the total counts by the area in which they were
counted and expressed per square millimetre. Analyses of the re-
lationship between protein pathology and microglia were con-
trolled for atrophy by partialling out the density of cell nuclei in
correlations, and accounting for this as a co-variate of no inter-
est in generalized linear models.
Data availability
The data that support the findings of this study are available
from the corresponding author, upon reasonable request.
Results
Summary demographics are outlined in Table 1, and
neuropsychological test scores, motor features, genetic
and CSF status for each participant are provided in
Table 2. Within the bvFTD group, two patients were
positive for pathogenic mutations in the microtubule
associated protein tau (MAPT) and three for expansions
in C9 open reading frame 72 (C9ORF72). One of the
nfvPPA group had a mutation in progranulin (GRN). CSF
or PET amyloid status was assessed in six participants
(four with svPPA, and two with nfvPPA), all of whom
were negative.
Group comparisons of
frontotemporal dementia with
controls
The repeated-measures ANOVA of regional 11C-PK-11195
binding across the FTD groups and controls, controlled for
age and sex, demonstrated a significant interaction between
region and diagnosis [F(37.4,423.5) = 3.54, P5 0.001]. T-
maps from the post hoc pairwise comparisons between the
control group and each disease group are shown in Fig. 1.
After correction for FDR, regions with significantly elevated
binding were (i) in the bvFTD group: bilateral superior
frontal gyri and putamen, right nucleus accumbens, left pos-
terior orbital gyrus, inferior frontal gyrus and middle frontal
gyrus; and (ii) in the svPPA group: left insula, middle and in-
ferior temporal gyri, right superior parietal gyrus, middle
and inferior temporal gyri, bilateral postcentral gyri, super-
ior temporal gyrus, parahippocampal and ambient gyri,
amygdala, inferior lateral anterior temporal lobe, medulla,
nuclei accumbens, medial anterior temporal lobe, fusiform
gyri. Left medial anterior and inferior lateral anterior tem-
poral lobe, and superior, middle and inferior temporal gyri
also survived Bonferroni correction. In the nfvPPA group no
differences survived FDR correction but the peak t-score
was in left inferior frontal gyrus [t(23) = 2.17, uncorrected
P = 0.04], which would be expected a priori to be the disease
epicentre (Rogalski et al., 2011).
The repeated measures ANOVA of regional 18F-AV-
1451 binding across the FTD groups and controls, con-
trolled for age and sex, showed a significant interaction
between region and diagnosis [F(33.6,403.6) = 3.80,
P5 0.001]. T-maps from the post hoc pairwise compari-
sons between the control group and each disease group
are shown in Fig. 1. After correction for FDR, significant-
ly elevated binding was seen in svPPA, in the following
regions: left amygdala, fusiform, medial anterior temporal
lobe, middle and inferior temporal gyri and superior tem-
poral gyrus, bilateral inferolateral anterior temporal lobes.
Left medial anterior temporal lobe and middle and infer-
ior temporal gyri also survived Bonferroni correction. For
bvFTD and nfvPPA, the group differences did not survive
FDR correction.
There was a trend towards patients with bvFTD due to
C9ORF72 having globally higher 11C-PK-11195 binding
than those with no genetic diagnosis, while those with
abnormalities of MAPT had intermediate binding [main ef-
fect of gene F(2,3) = 8.26, P = 0.060; Tukey’s HSD
P = 0.049 for C9ORF72 (mean = 0.176, ±0.017) versus no
Neuroinflammation in FTD BRAIN 2020: 143; 1010–1026 | 1013
genetic diagnosis (mean = 0.094, ±0.016), but non-signifi-
cant for either group versus MAPT (mean = 0.123,
±0.018)]. There was no significant interaction between gen-
etic diagnosis and region [F(5.3,7.8) = 1.47, P = 0.300].
There was no effect of bvFTD genetic status on 18F-AV-
1451 binding [main effect of gene F(2,4) = 0.85, P = 0.492;
interaction between gene and regional binding F(6.2,12.3) =
1.78, P = 0.183].
Table 1 Summary demographics and neuropsychometry
Group n M:F* Mean
age#,$
Education,
years*,#,$
ACE-R /100*,#,$,† MMSE/30,#,$ FAB/18 FTDRS_Logit FTDRS_Percent/100
nfvPPA 10 3:7 71 12 79 27 11 1.92 71.7
svPPA 11 9:2 68 14 63 25 12 0.74 52.8
bvFTD 10 5:5 60 13 57 22 8 –2.46 17.4
Tau controls 14 7:7 67 16 95 29 – – –
PK controls 15 7:8 69 14 92 29 – – –
Pairwise comparisons are by t-test for each demographic except sex comparison by v2.
*P5 0.05 significant pairwise comparison nfvPPA versus combined control group.
#F-test significant P5 0.05 across all groups.
$P5 0.05 significant pairwise comparison bvFTD versus combined control group.
†P5 0.05 significant pairwise comparison svPPA versus combined control group,
F = female; FAB = Frontal Assessment Battery; FTDRS = FTD Rating Scale; M = male; MMSE = Mini-Mental Status Examination.
Table 2 Demographics, neuropsychological testing, genetic/amyloid status and motor phenotype for each disease
participant
Case Diagnosis Gene/amyloid
status
Sex Entry
age
Education,
years
ACE-R /100 MMSE/30 FAB/18 FTDRS
Logit score
Motor
features
1 nfvPPA Ab–ve (CSF) M 55 14 93 29 15 3.35 –
2 nfvPPA – F 67 16 88 28 13 2.19 –
3 nfvPPA Ab–ve (CSF) F 62 11 90 27 15 1.92 +
4 nfvPPA – F 84 11 85 30 11 5.39 +
5 nfvPPA – F 81 10 78 28 15 0.16 –
6 nfvPPA – F 74 10 40 16 7 –0.8 –
7 nfvPPA GRN M 66 10 76 22 9 –0.2 –
8 nfvPPA – F 77 11 86 30 13 0.34 +
9 nfvPPA – M 74 11 87 30 10 1.47 +
10 nfvPPA – F 70 11 71 25 6 5.39 –
11 svPPA – M 77 16 45 22 11 –1.27 –
12 svPPA – M 69 16 77 28 11 –1.54 –
13 svPPA Ab–ve (CSF) M 61 15 79 30 16 –0.4 –
14 svPPA Ab–ve (PiB) F 65 18 72 27 16 – –
15 svPPA Ab–ve (CSF) M 67 17 71 27 17 2.49 –
16 svPPA Ab–ve (CSF) M 65 13 68 27 13 5.39 –
17 svPPA – M 72 13 63 25 12 1.26 –
18 svPPA – F 63 10 59 26 14 0.7 –
19 svPPA – M 69 18 85 30 14 2.19 –
20 svPPA – M 63 10 61 27 8 –0.8 –
21 svPPA – M 72 9 9 3 0 –0.59 –
22 bvFTD – F 63 12 79 29 11 –3.09 –
23 bvFTD – M 61 11 47 15 5 –2.18 –
24 bvFTD MAPT F 50 16 43 21 9 –3.8 –
25 bvFTD – M 75 16 68 21 6 –0.4 +
26 bvFTD MAPT F 70 16 38 14 7 –3.09 –
27 bvFTD – F 67 11 71 28 8 –0.8 –
28 bvFTD – M 51 14 81 29 11 –2.58 –
29 bvFTD C9orf72 M 56 10 53 25 6 –1.03 +
30 bvFTD C9orf72 F 51 10 41 16 7 –3.8 –
31 bvFTD C9orf72 M 58 9 46 17 5 –3.8 –
Ab–ve = negative tests for amyloid-b by CSF biomarkers or PiB PET scan. ACE-R = Addenbrooke’s Cognitive Examination Revised; FAB = Frontal Assessment Battery; FTDRS =
FTD Rating Scale; MMSE = Mini-Mental Status Examination; PiB = Pittsburgh compound B.
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For the patients with nfvPPA, the single patient with GRN
mutation was not significantly different from those without
a genetic diagnosis in binding of either 11C-PK-11195 [main
effect of gene F(1,6) = 0.38, P = 0.559; interaction between
gene and regional binding F(4.8,28.7) = 1.17, P = 0.349] or
18F-AV-1451 [main effect of gene F(1,6) = 0.1.66,
P = 0.244; interaction between gene and regional binding
F(3.2,19.2) = 0.47, P = 0.720].
Correlation of 11C-PK-11195 with
18F-AV-1451 in frontotemporal
dementia
Regional control-adjusted group mean 11C-PK-11195
BPND was strongly correlated with regional group mean
18F-AV1451 BPND in each group both before and after the
subtraction of the control group values in every region:
svPPA [r(81) = 0.727, P50.0001 before, r(81) = 0.883,
P5 0.0001 after], bvFTD [r(81) = 0.582, P5 0.0001 be-
fore, r(81) = 0.499, P5 0.0001 after], and nfvPPA [r(81) =
0.427, P5 0.0001 before, r(81) = 0.589, P5 0.0001 after]
(Fig. 2). These correlations were only slightly affected by
partialling out the effect of regional brain atrophy. For
svPPA r(80) = 0.634, P5 0.0001 [partial correlation be-
tween AV and atrophy r(80) = –0.398, P = 0.0002; PK and
atrophy r(80) = –0.330, P = 0.0024], for bvFTD r(80) =
0.459, P50.0001 [partial correlation between AV and at-
rophy r(80) = –0.020, P = 0.8576; PK and atrophy r(80) =
–0.360, P = 0.0009], and for nfvPPA r(80) = 0.542,
P5 0.0001 [partial correlation between AV and atrophy
Figure 1 Regional ligand binding by group. Unthresholded regional t-scores for each disease group compared to the control group for
11C-PK-11195 BPND on the left and
18F-AV-1451 BPND on the right.
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r(80) = –0.321, P = 0.0033; PK and atrophy r(80) = –0.048,
P = 0.6722].
Finally, to ensure that our methods for controlling for
non-specific general regional differences in PET tracer reten-
tion were adequate, we repeated our analysis in each lobe
separately. Across all three patient groups combined
(Supplementary Fig. 2), corrected for control binding, and
accounting for group with ANCOVA, significant associa-
tions were observed between 11C-PK11195 and 18F-AV1451
BPND in temporal lobe F(1,54) = 82.11, P5 0.0001
[diagnosis F(2,54) = 15.67, P5 0.0001, interaction F(2,54)
= 2.16, P = 0.12], insula and cingulate F(1,12) = 29.18,
P = 0.0002 [diagnosis F(2,12) = 25.82, P50.0001, inter-
action F51], frontal lobe F(1,66) = 52.88, P5 0.0001
[diagnosis F(2,66) = 32.31, P5 0.0001, interaction F(2,66)
= 7.41, P = 0.0013], parietal lobe F(1,12) = 24.3,
P = 0.0003 [diagnosis F(2,12) = 10.45, P50.0024, inter-
action F51], and deep nuclei F(1,24) = 27.42, P5 0.0001
[diagnosis F(2,24) = 8.07, P = 0.0021, interaction F(2,24) =
3.4, P = 0.05]. We did not find significant associations in
Figure 2 Scatter plot of the regional mean BPND for
11C-PK-11195 against regional mean BPND of
18F-AV-1451 by disease
group. For each disease group raw values are demonstrated on the left with values adjusted for non-specific signal strength through subtraction
of the regional control mean shown on the right.
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occipital lobe F5 1 [diagnosis F5 1, interaction F(2,12) =
4.92, P = 0.0275], cerebellum F(1,12) = 2.55, P = 0.1366
[diagnosis F(2,12) = 1.98, P = 0.1809, interaction F51], or
brainstem F5 1 [diagnosis F(2,9) = 1.69, P = 0.2388, inter-
action F5 1].
Principal component analysis of
11C-PK-11195 and 18F-AV-1451
Four principal components were detected in the 11C-
PK11195 BPND data before the elbow of the scree plot,
which together explained 64% of the variance in the data
(Fig. 3). Component 1 reflected whole brain binding.
Component 2 was strongly weighted to the bilateral anterior
temporal lobes. Component 3 primarily comprised frontal
binding with a right-sided predominance. Component 4 was
not strongly loaded onto any single region but was weighted
towards motor cortex. In a repeated measures ANOVA
including these four principal components, there was a main
effect of diagnosis [F(3,39) = 11.07, P5 0.001] and a sig-
nificant interaction between principal component weighting
and diagnosis [F(8.03, 104.36) = 4.16, P5 0.001]. After
correction for age and sex these remained significant [diag-
nosis F(3,34) = 8.98, P50.001; interaction between princi-
pal component weighting and diagnosis F(8.14,92.28) =
4.11, P5 0.001]; age and sex were not significant predictors
[age F(1,34) = 0.40, P = 0.533; sex F(1,34) = 1.45,
P = 0.237]. Post hoc t-tests between individual disease
groups and controls showed svPPA was associated with an
increase in component 2 [t(10.20) = 8.30, P5 0.001],
bvFTD associated with both increased component 2 [t(9.30)
= 3.37, P = 0.008] and component 3 [t(8.85) = 3.95,
P = 0.003] and nfvPPA associated with increased component
3 [t(12.4) = 2.38, P = 0.034] (Fig. 3). Components 1 and 4
Figure 3 First four principal components for 11C-PK-11195 and 18F-AV-1451. 18F-AV-1451 component 5 was also retained by Cattell’s
criterion but was not strongly weighted to any region and did not discriminate groups so is omitted here for parsimony. The bottom row shows,
for each principal component (PC), the difference between each patient group and controls, adjusted for age and sex in the repeated measures
ANOVA. Error bars span ± 1 SEM (standard error of the mean for the patient group). Significance in post hoc tests: ***P5 0.001, **P5 0.01,
*P5 0.05.
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did not significantly differ between controls and patient
groups.
Five principal components were detected in the 18F-AV-
1451 BPND data before the elbow of the scree plot, which
together accounted for 76% of the variance in the data.
Component 1 again reflected global binding but less marked
in the temporal poles, which were loaded onto component 2
(left) and component 4 (right). Component 3 was weighted
asymmetrically towards frontal lobe binding. Component 5
was not strongly loaded onto any single region but was
weighted towards bilateral superior temporal poles. In a
repeated measures ANOVA including these five principal
components, there was a main effect of diagnosis [F(3, 41)
= 5.43, P = 0.003] and a significant interaction between
principal component weighting and diagnosis [F(11,150.6)
= 3.68, P5 0.001]. After correction for age and sex these
remained significant [diagnosis F(3,36) = 3.80, P = 0.018;
interaction between principal component weighting and
diagnosis F(10.9,130.5) = 3.33, P50.001]; age was also a
significant predictor [F(1,36) = 4.47, P = 0.041] but sex was
not [F(1, 36) = 0.11, P = 0.743]. The bvFTD group had
increased weightings in component 4 [t(11.58) = 3.28,
P = 0.007], and svPPA had increased weightings in compo-
nent 2 [t(11.88) = 6.819, P5 0.0001] and component 4
[t(12.9) = 2.48, P = 0.028] (Fig. 3). There were no signifi-
cant post hoc differences between nfvPPA and controls.
Components 1, 3 and 5 did not differ significantly between
controls and patient groups.
In summary (Fig. 3), patients with bvFTD demonstrated
significantly elevated PK binding in spatial modes that
included frontal lobe and temporal poles, and elevated AV
binding in frontal regions; patients with svPPA demonstrated
significantly elevated AV and PK binding in temporal poles;
patients with nfvPPA demonstrated significantly elevated PK
binding in frontal lobe, but to a lesser extent than patients
with bvFTD, and they showed no spatial modes with ele-
vated AV binding.
Non-parametric analysis of
11C-PK-11195 and 18F-AV-1451
distributions
The principal component analyses suggest that a large
amount of the variance between subjects relates to whole
brain PET signal. While this might reflect global differences
in protein aggregation and neuroinflammation, it could also
be explained by variations in radioligand affinity for differ-
ent protein pathologies or other non-specific influences dis-
cussed below. We therefore performed an analysis of the
relative distribution of PET signal for each individual scan,
blinded to differences in overall signal magnitude by non-
parametric rank-order statistical methods.
Multi-dimensional scaling plots of the non-parametric
similarity between ligand distributions, for each subgroup
pair and for all groups combined, are shown in Fig. 4. The
CV-SVM classification accuracy and permutation-based
statistical significance are indicated next to each plot.
Classification was significantly better than chance in all
cases, except for the finding that the non-parametric distri-
bution of 18F-AV-1451 was unable to distinguish between
bvFTD and nfvPPA.
For those FTD participants that underwent scanning with
both ligands, the classification procedure was repeated after
combining the multi-dimensional scaling data such that the
CV-SVM operated on four dimensions rather than two. This
resulted in an improvement in the differentiation of bvFTD
and svPPA compared to either ligand alone (88.9% classifi-
cation accuracy, P5 0.001). Multimodal nfvPPA versus
svPPA classification accuracy matched the performance of
11C-PK-11195 at 100%, P5 0.001, but bvFTD versus
nfvPPA classification performance was intermediate com-
pared to each ligand alone, at 73.7%, P = 0.033.
This method was not able to classify participants based on
age or sex (Supplementary Fig. 3).
Post-mortem
immunohistochemistry
Representative post-mortem immunohistochemistry for pro-
tein aggregate inclusions and microglia are shown in Fig. 5.
The quantitative relationship between protein aggregation
and microglia is shown for each disease group individually
in Fig. 6.
A generalized linear model demonstrated a significant rela-
tionship between the overall density of pathology and the
density of microglia [Wald v2(1) = 21.40, P5 0.001],
accounting for subject factors (including age and sex) nested
within diagnostic group [Wald v2(8) = 79.55, P5 0.001],
brain region [Wald v2(3) = 18.06, P5 0.001], diagnosis
[Wald v2(3) = 3.95, P = 0.267], the interaction between
diagnosis and brain region [Wald v2(9) = 23.63, P = 0.005],
and the density of cell nuclei [Wald v2(1) = 21.12,
P5 0.001].
Repeat generalized linear models with the same design
demonstrated that this effect was driven by a significant rela-
tionship between the density of pathology and the density of
amoeboid (rounded, phagocytic, activated) microglia [Wald
v2(1) = 30.83, P5 0.001], but not the density of ramified
(dendritic, resting) microglia [Wald v2(1) = 0.02, P = 0.898].
Discussion
This in vivo study provides insights into complementary
pathophysiological processes of FTD. Taken as a whole, our
findings support an important role for neuroinflammation
across the FTD spectrum, corroborating suggestions from
epidemiological (Venneti et al., 2008; Lant et al., 2014), gen-
etic (Guerreiro et al., 2013; Rayaprolu et al., 2013; Broce
et al., 2018), imaging (Cagnin et al., 2004; Miyoshi et al.,
2010) and animal studies (Yoshiyama et al., 2007; Bhaskar
et al., 2010; Yin et al., 2010). Using regional ANOVA and a
principal components analysis, we have shown that
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Figure 4 Pairwise classification accuracy for each ligand. 11C-PK-11195 (left), 18F-AV-1451 (middle), and using combined data (right). The
graphs represent a 2D projection of the between-individual PET signal distribution dissimilarity calculated according to the squared metric stress
criterion. A 10-fold cross-validated support vector machine was applied to each plot, and the classification accuracy compared to a null distribu-
tion of 1000 randomizations for non-parametric significant testing. For each comparison, percentage classification and P-value is stated. In simple
terms, this means that the similarity of the distribution of ligand binding across the brain for each individual was assessed irrespective of the abso-
lute magnitude of binding (and therefore not determined by differences in ligand affinity for different pathological subtypes). Note how in the top
left plot (nfvPPA versus svPPA for 11C-PK-11195) two groups of patients are clearly separated. By contrast, in the second column third row
(bvFTD versus nfvPPA for 18F-AV-1451) the points are intermingled, with only chance-level classification.
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neuroinflammation (indexed by 11C-PK-11195) and protein
aggregates (tau or TDP43, as indexed by 18F-AV-1451) are
elevated in FTD (Figs 1 and 3). Furthermore, neuroinflam-
mation is regionally co-localized with protein aggregation
within the individual syndromes, including most strongly in
svPPA, where the predominant aggregated protein inclusions
are TDP-43 rather than tau (Fig. 2). Principal component
analysis revealed distinct spatial modes of neuroinflamma-
tion, with frontotemporal, temporal pole and global distri-
butions (Fig. 3). The weighting of these regional
distributions differs between groups, supporting the regional
differences in the pair-wise comparisons. The spatial modes
of protein aggregation (Fig. 3) similarly reflect the well char-
acterized distributions of pathology in each patient group.
However, the distribution of protein aggregation appears to
be less focal than neuroinflammation in nfvPPA. To identify
distinctive information from the patterns of inflammation
and aggregation, and control for the marked individual dif-
ferences in ligand binding affinity in different subtypes of
FTD, we used non-parametric multi-dimensional scaling and
cross-validated linear support vector machines to classify
patients. We demonstrated that the distribution of neuroin-
flammation can accurately distinguish the FTD syndromes
from controls and from each other (Fig. 4). Classification
was often possible based on the distribution of protein ag-
gregation, but with less accuracy. The greater discriminatory
ability of neuroinflammation emphasizes its potential mech-
anistic relevance to the pathophysiology of FTD. Despite
being strongly correlated at a regional level, the two PET
tracers carry some unique information across these condi-
tions, as illustrated by the improvement in distinguishing
bvFTD from svPPA when multi-modal data were jointly
available to the classifier.
The correlation between regional distributions of neuroin-
flammation and protein aggregation supports a close rela-
tionship between these processes in FTD, mirroring recent
evidence from Alzheimer’s disease that neuroinflammation is
correlated with tau aggregation (Dani et al., 2018), and
Figure 5 Immunohistochemistry from cases with FTLD-TDP43 types A and C, FTLD-P (Pick’s disease), and Alzheimer’s
disease (AD) at Braak stage V. Areas of low (visual cortex BA17/18) and high (temporal cortex, BA21/22) disease burden are shown. Scale
bars = 100 mm. Representative micrographs from the same location on adjacent sections stained for the relevant protein aggregate (phosphory-
lated-tau or TDP43) and CD68 (expressed by microglia), respectively.
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Figure 6 The relationship between protein aggregation and microglia in each post-mortem sample. Densities are quantified as
the number of microglia or pathological inclusions per square millimetre. Each point represents a single brain region in a single individual. The
Pearson correlation (r), and the partial correlation (q) after factoring out the density of cell nuclei are shown for each relationship, along with the
corresponding P-value. Trend lines are emboldened when both correlation and partial correlation were significant at a5 0.05.
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extending this to TDP-43 associated diseases. Further, we
confirm that this relationship is present throughout the dis-
ease course, by demonstrating it both in vivo with PET and
post-mortem with immunohistochemistry. The partial corre-
lations confirm that this association is over-and-above the ef-
fect of atrophy in FTD. While there were moderate
associations between ligand binding and atrophy in some
groups, in all cases these associations explained less of the
variance than the association between 11C-PK-11195 and
18F-AV-1451, suggesting that neuroinflammation and pro-
tein aggregation may be more tightly associated with each
other than either process is with volume loss. Similarly, in
the post-mortem sample the density of cell nuclei explained
some of the variance in the density of microglia, but add-
itional variance was explained by the density of pathology.
One interpretation of regionally co-localized neuroinflamma-
tion and protein aggregation is that microglial activation is
an early pathophysiological process, which promotes or
accelerates abnormal protein misfolding and aggregation.
Microglia play a key role in orchestrating the innate immune
response of the brain. They can be activated by misfolded
proteins, and mediate responses through inflammatory path-
ways, cytotoxicity and changes in plasticity (Nakajima and
Kohsaka, 2001; Nayak et al., 2014). In neurodegenerative
diseases, this state of activation may become chronic, dys-
functional, and toxic, contributing to pathogenicity
(Pasqualetti et al., 2015; Serrano-Pozo et al., 2016).
There is corollary evidence for inflammation in FTD
(Heneka et al., 2014), from genetic (Guerreiro et al., 2013;
Rayaprolu et al., 2013; Broce et al., 2018), CSF (Sjogren
et al., 2004; Woollacott et al., 2018), epidemiology (Miller
et al., 2013, 2016), post-mortem (Venneti et al., 2008; Lant
et al., 2014) and animal studies (Yoshiyama et al., 2007;
Bhaskar et al., 2010; Yin et al., 2010). It is well established
that an innate immune response, characterized by activated
microglia, is a feature of the neuropathology of FTD (Lant
et al., 2014). Furthermore, mutations leading to haplo-insuf-
ficiency of GRN, a growth factor that has peripheral im-
mune and central microglial regulatory functions (Petkau
et al., 2010; Yin et al., 2010; Pickford et al., 2011), produce
FTD syndromes characterized by TDP-43 pathology.
Expansions in C9ORF72 have effects on microglial function
as well as neurons (O’Rouke et al., 2016), and risk variants
for FTD in TREM2 are associated with microglial activation
(Giraldo et al., 2013). Neuroinflammation is an early feature
of pathophysiology in mouse models of tauopathy, where in-
flammatory changes precede the accumulation of aggregated
tau (Yoshiyama et al., 2007) and pro-inflammatory mole-
cules increase tau hyperphosphorylation and aggregation
(Bhaskar et al., 2010). In vivo PET studies in small samples
have shown that neuroinflammation anticipates atrophy in
clinically established FTD (Cagnin et al., 2004) and precedes
both symptoms and the detectability of tau aggregation by
PET in MAPT mutation carriers (Miyoshi et al., 2010;
Bevan-Jones et al., 2019). Although neuroinflammation
appears early in the pathogenesis of FTD and other neurode-
generative disorders, it remains unclear whether it is an
independently initiating factor or whether it is induced by
oligomeric proteins or pre-tangles.
Much of the evidence supporting the presence of inflam-
mation in FTD comes from ex vivo studies, and indeed we
provide further post-mortem evidence here. The need to im-
prove our understanding of this process during life has led
to the development of PET radioligands, but there is some
controversy over the optimum ligand for imaging activated
microglia. PET ligands, which target TSPO, have long been
the mainstay of imaging microglia. However TSPO expres-
sion patterns in microglia are complex and the functional
effects of different microglial phenotypes are incompletely
understood (Gomez-Nicola and Perry, 2015). TSPO is also
expressed by other cell types, notably astrocytes (McCarthy
and Harden, 1981). However, in favour of the use of 11C-
PK-11195 is its demonstrated selectivity for activated micro-
glia over quiescent microglia and reactive astrocytes (Banati,
2002), its relative insensitivity to common polymorphisms in
TSPO compared to second generation TSPO ligands
(Zhang, 2015; Stefaniak and O’Brien, 2016), and the fact
that it has well established methods of non-invasive kinetic
analysis (Turkheimer et al., 2007; Passamonti et al., 2018).
11C-PK-11195 has been used in studies of other neurodege-
nerative diseases (Edison et al., 2013; Varley et al., 2015;
Stefaniak and O’Brien, 2016; Passamonti et al., 2018).
There remain some disadvantages, including non-specific
binding and low brain penetration. Whilst its limited signal-
to-noise ratio might explain previous negative studies using
11C-PK-11195, this does not undermine positive findings
such as those shown here, especially within our multivariate
analyses that explicitly control for differences in ligand pene-
tration and affinity. When interpreting the meaning of
increased 11C-PK-11195 binding one must consider the po-
tential contribution from reactive astrocytes expressing upre-
gulated TSPO, and while increased 11C-PK-11195 binding
may still be interpreted as immune activation, a causal role
of inflammation in human dementia is yet to be proven by
interventional studies.
In contrast to 11C-PK-11195, the 18F-AV-1451 binding
provides an ambiguous signal despite protein aggregation
being an essential feature of FTD and many other dementias.
We propose that 18F-AV-1451 binding is a proxy measure of
aggregated non-amyloid-b proteins in FTD. In Alzheimer’s
disease the sensitivity of in vivo imaging with 18F-AV-1451,
and its affinity for tau in neurofibrillary tangles, is well estab-
lished and has contributed significantly to our understanding
of its pathogenesis and progression. However, the situation
in FTD is more complex due in part to pathological hetero-
geneity and the differential affinity for tau aggregates arising
from different isoforms and with different ultrastructure
(Jones et al., 2018). The molecular target in FTD associated
with TDP43 is also as yet undetermined, but is unlikely to be
TDP43 itself (Marquie´ et al., 2015; Lowe et al., 2016;
Sander et al., 2016). This heterogeneity is problematic for
univariate regional analyses, and although six of our patients
have genetic mutations, and six others were amyloid
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biomarker negative (Tables 1 and 2), we cannot definitively
state the majority of patients’ pathological type ante-mortem.
The molecular targets for 18F-AV-1451 binding remain
controversial, and several off-target binding possibilities
need to be considered. Supporting our use of 18F-AV-1451
as a marker of non-amyloid-b protein aggregation, previous
post-mortem work has demonstrated some binding to FTLD
pathologies, albeit at a lower magnitude than that seen with
Alzheimer’s pathology (Marquie´ et al., 2015; Lowe et al.,
2016; Mcmillan et al., 2016; Sander et al., 2016). This is
corroborated by in vivo studies of patients with a straight
filament 4-repeat tauopathy and clinical FTD resulting from
MAPT mutations, showing binding in areas typically
affected in FTD and affected at post-mortem (Bevan-Jones
et al., 2016; Smith et al., 2016), and by the elevated binding
in the affected brain regions of patients with svPPA (Bevan-
Jones et al., 2018a, Makaretz et al., 2018) and bvFTD due
to C9orf72 expansions (Bevan-Jones et al., 2018b), who
have TDP-43 rather than tau pathology. However, even
within genetically determined FTD, binding affinity varies
according to different tau isoforms and strains (Jones et al.,
2018) supporting varying affinity to different morphologies
of tau.
18F-AV-1451 can have other non-tau, non-TDP-43, tar-
gets such as neuromelanin (Marquie´ et al., 2015) and mono-
amine oxidase (MAO) (Vermeiren et al., 2018), and such
off-target binding is an important caveat in clinical studies
using 18F-AV-1451 (Baker et al., 2019). Neuromelanin in
the catecholaminergic brainstem nuclei is a particular con-
cern in studies of brainstem tau pathology in progressive
supranuclear palsy, and artefactual binding in Parkinson’s
disease. However, neuromelanin is not expressed by cortex
even in tauopathies (Passamonti et al., 2018) and is unlikely
to account for our FTD results. MAO subtypes are
expressed by both neurons (MAOA, especially in basal gan-
glia) and reactive astrocytes (mainly MAOB) (Fowler et al.,
2005; Ben Haim et al., 2015). If 18F-AV-1451 binding were
driven by ‘off target’ binding to reactive astrocytes, which
are induced by activated microglia (Liddelow et al., 2017),
this would provide further evidence for the importance of
neuroinflammation in FTD, but it would undermine the in-
ference we make on the relationship between protein aggre-
gation and inflammation. Although 18F-AV-1451 has weak
affinity for both types of MAO (Drake et al., 2019), selective
blockade of MAOA and MAOB leads to only minor
changes in the estimated cortical binding from PET in non-
human primates (Drake et al., 2019), while clinical treat-
ment with MAO inhibitors does not significantly change
estimated 18F-AV-1451 uptake in humans (Hansen et al.,
2018; Smith et al., 2018). Moreover, the presymptomatic
dissociation of 11C-PK-11195 and 18F-AV-1451 binding
(Bevan-Jones et al., 2019) argues strongly against simple
cross-affinity. Similarly, in our own post-mortem cases we
see regional co-localization of both FTD-tau and FTD-TDP-
43 aggregates with microglial activation, to at least as great
a degree as is observed in Alzheimer’s disease (Fig. 6).
Together, these observations suggest that neuroinflammation
and protein aggregation co-occur in symptomatic stages, but
in early stage disease neuroinflammation can occur in the
absence of 18F-AV-1451 binding. Neuroinflammation and
protein aggregation are at least partially dissociable proc-
esses by current PET ligands.
In the face of uncertainty about molecular targets and var-
iations in affinity, it is important to emphasize that through
our classification analysis we focus on distribution rather
than quantification of binding, using a non-parametric
method that is insensitive to absolute binding values and in-
stead reflects the spatial pattern of binding. This takes into
account the potential differences in affinity of 18F-AV-1451
for different protein targets. Overall, whilst it is clear that
18F-AV-1451 does not bind exclusively to tau aggregates,
the distribution of binding regionally co-localizes and varies
with that expected of aggregated protein in these diseases,
and post-mortem immunohistochemistry of tau. Indeed, 18F-
AV-1451 may provide a usefully non-selective marker of
non-amyloid-b aggregated protein, whether tau or TDP-43,
allowing in vivo examination across the spectrum of sporad-
ic FTD syndromes. Whilst in the complex setting of FTLD
we interpret 18F-AV-1451 binding as a non-specific marker
of non-amyloid-b neuropathology, the biological relevance
of elevated binding in non-Alzheimer’s disease neurodegener-
ative disease remains incompletely understood. Further work
examining 18F-AV-1451 binding across large post-mortem
cohorts of FTLD pathology will be required to independent-
ly validate our hypothesis.
The main limitation of this study is group size which, al-
though larger than most previous PET studies in FTD, is still
small for each individual diagnosis. The small sample size
reduces the power of the study to find parametric group dif-
ferences in binding, particularly given that both ligands have
a degree of insensitivity to their targets, as well as limiting
the ability to detect associations with clinical features and se-
verity. Characterization of the groups is also limited in that
the genotyping and amyloid assays were based on clinical
indications and consent: we did not directly examine amyl-
oid status in all individuals and whilst there is a mix of both
genetic and sporadic cases, we did not genotype every par-
ticipant. The inability to perform pathological subtyping
in vivo makes interpretation of results more difficult in view
of the generally poor relationship between phenotype and
underlying neuropathology in FTD. Consequently, we can-
not use the clinical diagnostic groups alone to draw conclu-
sions about the relationship between microglial activation
and specific forms of protein aggregation. We are also lim-
ited in the inferences about the predilection for immune dys-
regulation in a particular neuropathological subtype, such as
the relationship suggested between immune dysfunction and
FTLD-TDP-43 (Miller et al., 2013, 2016), except for the
cases with genetic mutations.
To conclude, we provide in vivo evidence for neuroinflam-
mation in FTD, which has a close relationship with 18F-AV-
1451 binding, taken in this study to represent a marker of
either FTLD-tau or FTLD-TDP-43 neuropathology. PET
measurement of inflammation provided a more accurate
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classification of syndromes than did protein aggregation
emphasizing its potential importance in shaping the clinical
and neuropathological patterns of the diverse clinical syn-
dromes of FTD. A causal role for neuroinflammation in neu-
rodegeneration would inform future drug targets and
potential clinical trials in FTD. Our findings therefore war-
rant further longitudinal mechanistic investigation into the
role of neuroinflammation in early-stage neurodegeneration,
its relationship to specific protein aggregation and to clinical
progression.
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